Our DNA
ReceptorPharma is an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. Our primary focus is Alzheimer with a novel mode of action
Receptorpharma
Do something of consequence
Science
Our primary focus is Alzheimer with a novel mode of action
Future
Acquiring novel nano technology and creations of New Molecular Entity.
Social responsibility
Several silver economy collaborations of new technologies to patients and physicians.
ReceptorPharma AB
ReceptorPharma AB is a Swedish orphan receptor drug discovery company, founded in Nov 2017, with a unique disruptive business approach and fearlessness, enabling us to walk less traveled unique paths to create the company that we want.
Our business idea is enabled by a very lean, ambitious, and motivated team with expertise and know-how within orphan receptors and early stage companies, in conjunction with global timing and quite a few dashes of serendipity. ReceptorPharma will actually have the opportunity to try to go after some of the largest crippling diseases that are plaguing the world, including Alzheimer’s, Parkinson’s and Cancer.
Today, ReceptorPharma consists of founders from the classical giants of big pharma including almost 100 years of combined experience. These inventors are crucial as we filled the patents surrounding the most interesting and potential drug discovery substance in the last decade. The company is led by a serial entrepreneur and Chief Executive Officer (CEO) Zacharia Ressaissi. The Advisory Board Chairman Andreas Anderhov, M.B.A., and 20 years of working in the pharmaceutical CNS industry, as well as within medical devices in several different roles will be leading up the global team. Currently positioning in Australia he will including the Asian Pacific markets from the start of licensing agreements being established. Our Chief Scientific Officer (CSO) Marguérite Mensonides-Harsema, Ph.D will lead the R&D and execution of the drug development heading into clinical trials. We are placed in the United States and work with several major Universities to start a clinical trial in Q1 2022.
Looking Ahead
For the future we will investigate the nano technology creations of new molecular structures and the repositioning of previous substances, as they have breakthrough technology accompanying the on re-trials leading to a road in the near future including our CRO capacity with the MAX IV Laboratory in Lund
Technology & Humans
Our commitment to innovative pharmaceutical development to better patient care is measured not only by our focus on pharmacology but collaborations in new technologies to patients and physicians, an importance we place on making an impact within the communities where we work and live
